

POSTER PRESENTATION



P085: Surveillance of drug-resistant Salmonella sp and Shigella sp infections in Rwanda

JB Gatabazi

From 2nd International Conference on Prevention and Infection Control (ICPIC 2013) Geneva, Switzerland. 25-28 June 2013

Introduction

Salmonella sp. and Shigella sp infections are public health threat worldwide, particularly in Sub-Saharan Africa including in Rwanda. This study was done to identify Salmonella sp. and Shigella sp. currently circulating in Rwanda and determine their drug susceptibility pattern.

Objectives

To determine the prevalence of *Salmonella spp.* and *Shigella spp.* strains circulating in Rwanda and their susceptibilty pattern in Rwanda.

Methods

196 blood and 24 stool specimens from patients were analyzed in Laboratory of Rwanda for culture isolation, identification and drug-sensitivity testing.

Results

91 (92.2 %) of them were identified as *Salmonella enterica* serovar Typhi, 10 were *Shigella sp.* The isolates were subsequently subjected to antibiotic susceptibility tests and the strains of *S*.Typhi isolates were found to be susceptible to cefotaxime (100%), and ciprofloxacin (97.9 %) and resistant to nalidixic acid (89.4%), cotrimoxazole (87.2%). With regard to *Shigella* infections, the antibiotics which showed 100% susceptibility to all species identified were ciprofloxacine, cefotaxime, ceftazidine.

Conclusion

The prevalent *Salmonella* strain circulating in Rwanda is *S*.Typhi and two most useful drugs of choice to treat *Salmonella sp.* and *Shigella sp.* infections in Rwanda are cefotaxime and ciprofloxacin.

Laboratory Department, Rwanda Military Hospital Kigali, Kigali, Rwanda

Disclosure of interest None declared.

Published: 20 June 2013

doi:10.1186/2047-2994-2-S1-P85 Cite this article as: Gatabazi: P085: Surveillance of drug-resistant Salmonella sp and Shigella sp infections in Rwanda. Antimicrobial Resistance and Infection Control 2013 2(Suppl 1):P85.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit



© 2013 Gatabazi; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.